Cargando…
2431: Characterization of immune cell differences with anti-thymocyte globulin (ATG) and granulocyte colony stimulating factor (GCSF) in both preclinical and clinical models of type 1 diabetes
OBJECTIVES/SPECIFIC AIMS: Understand the immunomodulatory effects of anti-thymocyte globulin (ATG) and granulocyte colony stimulating factor (G-CSF) on type 1 diabetes patients using samples and in the preclinical model, the nonobese diabetic mouse. METHODS/STUDY POPULATION: Flow cytometry analysis...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cambridge University Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6798906/ http://dx.doi.org/10.1017/cts.2017.136 |
_version_ | 1783460161138982912 |
---|---|
author | Lin, Andrea Mathews, Clayton Haller, Michael Brusko, Todd Atkinson, Mark Flynn, Ryan |
author_facet | Lin, Andrea Mathews, Clayton Haller, Michael Brusko, Todd Atkinson, Mark Flynn, Ryan |
author_sort | Lin, Andrea |
collection | PubMed |
description | OBJECTIVES/SPECIFIC AIMS: Understand the immunomodulatory effects of anti-thymocyte globulin (ATG) and granulocyte colony stimulating factor (G-CSF) on type 1 diabetes patients using samples and in the preclinical model, the nonobese diabetic mouse. METHODS/STUDY POPULATION: Flow cytometry analysis of phase 1 peripheral blood samples treatment of nonobese diabetic mouse with ATG and GCSF and flow cytometry analysis of immune organs (spleen, lymph nodes, blood, bone marrow). RESULTS/ANTICIPATED RESULTS: Changes in both innate and adaptive immune cell subsets including plasmacytoid dendritic cells, naive, memory, effector CD4+ and CD8+ T-cells, and CD4+ T-regulatory cells and CD8+ T-regulatory cells DISCUSSION/SIGNIFICANCE OF IMPACT: Understanding of immune cell targets for immunotherapy in new-onset type 1 diabetes patients. |
format | Online Article Text |
id | pubmed-6798906 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Cambridge University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-67989062019-10-28 2431: Characterization of immune cell differences with anti-thymocyte globulin (ATG) and granulocyte colony stimulating factor (GCSF) in both preclinical and clinical models of type 1 diabetes Lin, Andrea Mathews, Clayton Haller, Michael Brusko, Todd Atkinson, Mark Flynn, Ryan J Clin Transl Sci Clinical Trial OBJECTIVES/SPECIFIC AIMS: Understand the immunomodulatory effects of anti-thymocyte globulin (ATG) and granulocyte colony stimulating factor (G-CSF) on type 1 diabetes patients using samples and in the preclinical model, the nonobese diabetic mouse. METHODS/STUDY POPULATION: Flow cytometry analysis of phase 1 peripheral blood samples treatment of nonobese diabetic mouse with ATG and GCSF and flow cytometry analysis of immune organs (spleen, lymph nodes, blood, bone marrow). RESULTS/ANTICIPATED RESULTS: Changes in both innate and adaptive immune cell subsets including plasmacytoid dendritic cells, naive, memory, effector CD4+ and CD8+ T-cells, and CD4+ T-regulatory cells and CD8+ T-regulatory cells DISCUSSION/SIGNIFICANCE OF IMPACT: Understanding of immune cell targets for immunotherapy in new-onset type 1 diabetes patients. Cambridge University Press 2018-05-10 /pmc/articles/PMC6798906/ http://dx.doi.org/10.1017/cts.2017.136 Text en © The Association for Clinical and Translational Science 2018 http://creativecommons.org/licenses/by/4.0/ This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Clinical Trial Lin, Andrea Mathews, Clayton Haller, Michael Brusko, Todd Atkinson, Mark Flynn, Ryan 2431: Characterization of immune cell differences with anti-thymocyte globulin (ATG) and granulocyte colony stimulating factor (GCSF) in both preclinical and clinical models of type 1 diabetes |
title | 2431: Characterization of immune cell differences with anti-thymocyte globulin (ATG) and granulocyte colony stimulating factor (GCSF) in both preclinical and clinical models of type 1 diabetes |
title_full | 2431: Characterization of immune cell differences with anti-thymocyte globulin (ATG) and granulocyte colony stimulating factor (GCSF) in both preclinical and clinical models of type 1 diabetes |
title_fullStr | 2431: Characterization of immune cell differences with anti-thymocyte globulin (ATG) and granulocyte colony stimulating factor (GCSF) in both preclinical and clinical models of type 1 diabetes |
title_full_unstemmed | 2431: Characterization of immune cell differences with anti-thymocyte globulin (ATG) and granulocyte colony stimulating factor (GCSF) in both preclinical and clinical models of type 1 diabetes |
title_short | 2431: Characterization of immune cell differences with anti-thymocyte globulin (ATG) and granulocyte colony stimulating factor (GCSF) in both preclinical and clinical models of type 1 diabetes |
title_sort | 2431: characterization of immune cell differences with anti-thymocyte globulin (atg) and granulocyte colony stimulating factor (gcsf) in both preclinical and clinical models of type 1 diabetes |
topic | Clinical Trial |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6798906/ http://dx.doi.org/10.1017/cts.2017.136 |
work_keys_str_mv | AT linandrea 2431characterizationofimmunecelldifferenceswithantithymocyteglobulinatgandgranulocytecolonystimulatingfactorgcsfinbothpreclinicalandclinicalmodelsoftype1diabetes AT mathewsclayton 2431characterizationofimmunecelldifferenceswithantithymocyteglobulinatgandgranulocytecolonystimulatingfactorgcsfinbothpreclinicalandclinicalmodelsoftype1diabetes AT hallermichael 2431characterizationofimmunecelldifferenceswithantithymocyteglobulinatgandgranulocytecolonystimulatingfactorgcsfinbothpreclinicalandclinicalmodelsoftype1diabetes AT bruskotodd 2431characterizationofimmunecelldifferenceswithantithymocyteglobulinatgandgranulocytecolonystimulatingfactorgcsfinbothpreclinicalandclinicalmodelsoftype1diabetes AT atkinsonmark 2431characterizationofimmunecelldifferenceswithantithymocyteglobulinatgandgranulocytecolonystimulatingfactorgcsfinbothpreclinicalandclinicalmodelsoftype1diabetes AT flynnryan 2431characterizationofimmunecelldifferenceswithantithymocyteglobulinatgandgranulocytecolonystimulatingfactorgcsfinbothpreclinicalandclinicalmodelsoftype1diabetes |